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Selective suppression of the α isoform of
p38 MAPK rescues late-stage tau pathology
Nicole Maphis1, Shanya Jiang1, Guixiang Xu2, Olga N. Kokiko-Cochran3, Saktimayee M. Roy4, Linda J. Van Eldik5,
D. Martin Watterson4, Bruce T. Lamb2 and Kiran Bhaskar1*
Abstract
Background: Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer’s
disease and related tauopathies. We previously demonstrated that the microglial activation induces tau
hyperphosphorylation and cognitive impairment via activation of p38 mitogen-activated protein kinase (p38 MAPK)
in the hTau mouse model of tauopathy that was deficient for microglial fractalkine receptor CX3CR1.
Method: We report an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α
MAPK (MW181) and its effects on tau phosphorylation in vitro and in hTau mice.
Results: First, pretreatment of mouse primary cortical neurons with MW181 completely blocked inflammation-
induced p38α MAPK activation and AT8 (pS199/pS202) site tau phosphorylation, with the maximum effect peaking
at 60–90 min after stimulation. Second, treatment of old (~20 months of age) hTau mice with MW181 (1 mg/kg
body weight; 14 days via oral gavage) significantly reduced p38α MAPK activation compared with vehicle-
administered hTau mice. This also resulted in a significant reduction in AT180 (pT231) site tau phosphorylation and
Sarkosyl-insoluble tau aggregates. Third, MW181 treatment significantly increased synaptophysin protein expression
and resulted in improved working memory. Fourth, MW181 administration reduced phosphorylated MAPK-activated
protein kinase 2 (pMK2) and phosphorylated activating transcription factor 2 (pATF2), which are known substrates
of p38α MAPK. Finally, MW181 reduced the expression of interferon-γ and interleukin-1β.
Conclusions: Taken together, these studies support p38α MAPK as a valid therapeutic target for the treatment of
tauopathies.
Keywords: p38 mitogen activated protein kinase, Alzheimer’s disease, tau, tauopathies, hTau, SB239063, p38 MAPK
inhibitor, MW01-10-181SRM, MW181 and MK2 deficiency
Background
Alzheimer’s disease (AD), a progressive neurodegenera-
tive condition, is diagnosed in 60–80% of total dementia
cases and presents with memory loss and other cognitive
impairments. AD is the sixth leading cause of death in
the United States. Neurofibrillary tangle (NFT) path-
ology, one of the major pathological hallmarks of AD
and related tauopathies, occurs when microtubule-
associated protein tau (MAPT or tau) undergoes hyper-
phosphorylation and aggregates as NFTs. Recent studies
suggest that NFT pathology closely correlates with neu-
rodegeneration and cognitive decline [1, 2].
Over the years, studies have suggested that one of the
major functions of tau is to bind and stabilize microtu-
bules. However, immune-mediated or genetic-mediated
depletion of tau did not seem to affect microtubule sta-
bility in vitro and in vivo, suggesting the possibility of
non-microtubule binding functions of tau [3, 4]. Indeed,
our previous studies have suggested that the PXXP motif
of tau can interact with SH3 domains of the Src family
kinases (such as Fyn and Src) [5–7], which in turn affect
actin remodeling in growth cones [7]. These tau–fyn [8]
and tau–actin [9] (also reviewed in [10]) interactions
were also demonstrated in earlier studies. The non-
microtubule binding functions of tau are equally
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important because a recent study demonstrated that tau
has a very short interaction time with microtubules in
physiological conditions [11]. Based on these studies, the
current consensus in the field is that tau can contribute
to the disease process either via loss of function (e.g.,
failure to bind to microtubules) or gain of toxic function
(e.g., by affecting various types of non-microtubule bind-
ing functions). In further support of this, our previous
studies have demonstrated that phosphorylation or
disease-related point mutations in tau affect tau–Fyn in-
teractions and may contribute to pathogenesis [12, 13].
Therefore, phosphorylation of tau by various Ser/Thr or
Tyr kinases may directly impact on both microtubule-
binding and gain of toxic functions of tau, which may
contribute to neurodegeneration in AD [14, 15]
(reviewed in [16, 17]). Most of these tau phosphorylation
sites are considered to be targeted by more than one
kinase [18]. In fact, there are currently more than 20
serine/threonine kinases reported to phosphorylate tau in
vitro: glycogen synthase kinase 3 beta (GSK-3β), cyclin-
dependent kinase 5 (Cdk5), microtubule affinity regulating
kinase 1–4 (MARK1–MAPK4), extracellular signal-
related kinase (ERK), p38 mitogen-associated protein kin-
ase alpha (p38α MAPK), and c-Jun N-terminal kinase
(JNK) are the best examples [19–21]. However, their dir-
ect involvement in AD remains elusive and those kinases
amenable to therapeutic intervention are not yet evident.
We have demonstrated recently that activated microglia
induced tau hyperphosphorylation via activation of the
p38α MAPK signaling pathway in the hTau mouse model
of tauopathy [22, 23]. Notably, we observed elevated levels
of active (phosphorylated) p38α MAPK, but not GSK3β or
regulators (p35/p25) of Cdk5, correlating with increased
tau phosphorylation in the hippocampus of hTau mice defi-
cient for the chemokine receptor CX3CR1 [22]. This is
consistent with a previous in vitro study in which neocor-
tical neurons pretreated with the popular-mixed kinase
inhibitor SB203580 and then treated with interleukin-1β
(IL-1β) showed significantly reduced tau phosphorylation
and restored synaptophysin levels [24]. Signaling through
p38 MAPK, especially the p38α isoform, has also been dis-
covered recently to be a critical component for cytokine
production in activated microglia [25, 26]. The p38α-
mediated cytokine overproduction in microglia has been
linked to inflammation-induced neurotoxicity in a var-
iety of mouse models [22, 27–33]. These studies sug-
gest that targeting the p38α MAPK signaling pathway
should be tested as a potential strategy to suppress
microglial innate immune responses and prevent
inflammation-mediated tau pathology.
The p38α MAPK has been a drug target in many animal
models of disease, including peripheral inflammatory dis-
orders (e.g., asthma and rheumatoid arthritis) and central
nervous system (CNS) disorders. A variety of small-
molecule p38α MAPK inhibitors have been tested in pre-
clinical animal models of CNS diseases. These inhibitors
vary in their target specificity, which raises concerns about
linkage of target modulation to phenotype—a key aspect
of drug discovery target validation, as documented previ-
ously [34]. For example, first-generation p38α MAPK in-
hibitors such as MW01-2-069A-SRM were used in a
mouse model of AD-relevant pathophysiology that in-
volves intracerebroventricular (ICV) infusion of oligo-
meric Aβ1–42 [35]. Other studies used commercially
available mixed kinase inhibitors such as SB203580,
SB239063, and FR167653 in models of amyotrophic lateral
sclerosis [32], contusion model of spinal cord injury [33],
controlled cortical impact model of traumatic brain injury
[36], cerebral ischemia [37], neuropathic pain in a rat
model of lumbar disc herniation [38], cerebral ischemia in
a rat model of stroke [39], and Parkinson’s disease in
MPTP-treated mice [40]. While kinase inhibition resulted
in significant neuroprotection in a majority of these
models, it failed to restore function in some models (e.g.,
spinal cord injury). However, none of the previous studies
carefully characterized or investigated p38α MAPK inhibi-
tors in vivo for their independent effects on amyloid and
tau pathologies, which are each relevant to AD and related
non-AD tauopathies.
In the current study, we have utilized MW01-10-
181SRM (or MW181), a highly selective p38α MAPK in-
hibitor [26], for its effects on p38α MAPK activity and
tau phosphorylation in vitro and in 20-month-old hTau
mice with advanced stages of disease. We report here
that MW181 suppresses p38α MAPK activation, reduces
tau phosphorylation, and decreases proinflammatory
cytokine production. We also show that MW181 may
prevent cognitive impairment in the aged hTau mice,
possibly attributed to increasing synaptophysin levels.
The data with MW181 were compared in several key ex-
periments with results obtained using the mixed kinase
inhibitor SB239063. In most experiments the results
were congruent, allowing normalization of our results to
those in the literature. The results with MW181, how-
ever, were remarkable in their further validation of p38α
MAPK as a potential therapeutic target for tauopathies.
Methods
In-vitro experiments
Primary cortical neuronal cultures
Neuronal cultures were prepared from embryonic day
16.5 (E16.5) C57BL/6 J mouse embryos as described pre-
viously [41]. Primary cortical neurons were seeded onto
poly-L-lysine coated six-well plates at a density of 0.5 ×
106 cells/well for conditioned media (CM) experiments
(Fig. 1a). Cultures were grown for 21 days in vitro (DIV)
at 37 °C in neurobasal media with B-27 supplement in
humidified 5% CO2/95% air prior to any treatment.
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Primary microglial culture
Microglial cultures were prepared from postnatal day 3
(P3) pups from Cx3cr1–/– mice litters [42] as described
previously [43]. Briefly, mixed glial cells were first cul-
tured and grown in a T-75 cm2 flask seeded at a density
of 1.0 × 105–1.2 × 105 cells/cm2 in 10% fetal bovine
serum/Dulbecco’s modified eagle medium (FBS/DMEM
F12 or complete growth media). After 14 DIV, a differ-
ential trypsinization [43] protocol was utilized to remove
the astrocytes in the flasks and the pure population of
Fig. 1 SB239063 and MW181 reduce inflammation-induced hyperphosphorylation of tau, p38α MAPK, and ATF2 activation in primary neurons. a Sche-
matic showing 30-min pretreatment of 21 DIV Cx3cr1+/+ primary cortical neurons with MW181 (2 μM), SB239063 (100 μM), or vehicle (Veh) followed by
treatment with 25% Cx3cr1–/– microglial conditioned media (CM) for 90 min prior to biochemical analysis of neuronal lysates. b, c Structural formulae
of SB239063 (adapted from [68]) and MW181 (adapted from [26]). d, e Cx3cr1–/– microglial CM significantly induced tau phosphorylation on AT8 and
AT180 sites. Pretreatment of neurons with SB239063 or MW181 significantly reduced CM-induced tau phosphorylation on AT8 and AT180 sites.
Quantifications are shown in e (n = 3 independent cultures, mean ± SEM of integrated density value (IDV) ratios as labeled. *p < 0.05; ***p < 0.001; one-
way ANOVA with Tukey’s multiple comparison test). f–i MW181 (f) or SB239063 (g) neuronal treatment showing reduction in the activated p-p38α
MAPK (pT180/pY182) and AT8 site tau phosphorylation with a maximum reduction at 60 and 90 min time points (for MW181), and at 20 and 60 min
time points (for SB239063) post CM treatment, which was considered as 0 min. Quantifications are shown in h (for MW181) and i (for SB239063). N = 3
independent cultures, mean ± SEM of IDV ratios as labeled. j, k Elevated levels of phosphorylated ATF2 (pT71) at 90 min after Cx3cr1–/– microglial CM
treatment. The pATF2 level was reduced by 30-min pretreatment with SB239063 and MW181. Quantifications are shown in k (n = 3 independent
cultures, mean ± SEM of IDV ratios of pATF2/GAPDH; **p < 0.01; ***p < 0.001; one-way ANOVA with Tukey’s multiple comparison test)
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microglia was seeded at a density of 0.25 × 106 cells/well
in a six-well plate (Fig. 1a) in 2% FBS/DMEM to ensure
adherence. Next, the complete growth media were re-
placed with neurobasal media (with no B27 supplement)
24 h prior to the co-culture experiment to match the cul-
ture media of primary neurons for CM studies (see later).
Neuron-microglia CM experiments and pharmacokinetics
Primary neuronal and microglial cultures were prepared
as already described. 21 DIV primary cortical neurons
were pretreated for 30 min with p38α MAPK inhibitors
(SB239063, 100 μM (catalog number S0569; Sigma) dis-
solved in DMSO; or MW181, 2 μM dissolved in
saline—0.9% NaCl/H2O, pH 7.4) or VEH (saline). After
30 min, 25% of the media was removed from each well
with primary neurons and was replaced with Cx3cr1–/–
microglia CM (harvested just before adding to the neur-
onal wells without any prior centrifugations). After
90 min, neurons were lysed in 1× lithium dodecyl sulfate
(LDS) sample buffer with sample reducing agent (RA)
buffer (a total volume of 100 μl per two wells in a six-
well plate) and sonicated for 30 seconds. For the time-
course experiments, neurons were first pretreated with
the p38α MAPK inhibitors (SB239063 at 100 μM final
concentration or MW181 at 2 μM final concentration)
or vehicle (saline) 30 min prior to the addition of
Cx3cr1–/– microglia CM. We chose 2 μM for MW181
based on our previous studies where a dose of 5 μM
showed significantly reduced levels of IL-1β by LPS-
stimulated BV2 cells [26]. Similarly, 100 μM of
SB239063 was selected based on a previous study where
84% downregulation of IL-1β mRNA was observed in
microglial cells in an organotypic hippocampal slice cul-
ture model [44]. At 20, 40, 60, and 90 min after the
addition of the Cx3cr1–/– microglia CM, the neuronal ly-
sates were prepared as already described. All experi-
ments were performed in triplicate with independent
cultures.
In-vivo experiments
Mice
The hTau [45] (expressing human MAPT and deficient for
endogenous mouse Mapt) mice were bred and maintained
in our colony. MK2–/– mice [46] were a kind gift from Dr
Matthias Gaestel, Medical School Hannover, provided by
Dr Ellen Beswick at the University of New Mexico. Both
hTau and MK2–/– mice were in the C57BL/6 J back-
ground. We utilized mixed genders of these mice in the
present study (Table 1). All experimental protocols involv-
ing animals were performed in accordance with the US
National Institutes of Health guidelines on animal care
and were approved by the Institutional Animal Care and
Use Committees of both the University of New Mexico
and the Cleveland Clinic Foundation.
Oral Gavage (p.o.) experiments
The hTau mice (20 months of age) were divided into
three groups and were administered: SB239063 (in 0.1%
dimethyl sulfoxide (DMSO) in H2O, with 50% polyethyl-
ene glycol (PEG) 400 and carboxymethyl cellulose as de-
scribed previously [47] and at a final concentration of
5 mg/kg, body weight (b.w.)); MW181 (dissolved in 0.9%
saline; administered at a final concentration of 1 mg/kg,
b.w.); or saline (vehicle) orally using an 18-gauge stain-
less steel oral gavage needle (catalog number FNS-18-2;
Kent Scientific) daily, over the course of 14 days. All ani-
mals receiving treatment were monitored for weight
loss/gain, grooming changes and posture over 14 days;
no differences were noted. We selected 1 mg/kg MW181
based on our previous study, where 5 mg/kg b.w. of
MW181 was able to attenuate Aβ-induced synaptic and
cognitive dysfunction in a mouse model of AD [26]. Follow-
ing the treatment, animals were sacrificed (described later).
LPS injections
Lipopolysaccharide (LPS, catalog number L2630; Sigma)
was obtained from phenol-extracted E. coli and the ly-
ophilized powder was dissolved in Hanks’ balanced salt
solution (HBSS, catalog number H9269; Sigma) at a
stock concentration of 1 mg/ml. Nontransgenic and
MK2–/– mice were treated with a single dose of LPS
(10 mg/kg, b.w., intraperitoneally (i.p.)). Animals were
sacrificed 24 h post injection as described later.
Antibodies and reagents
MAPT antibodies
The following antibodies against tau were used: AT8
(pS199/pS202), AT180 (pT231), and Tau5 (Thermo
Table 1 Genotype, group size, gender, and age of the mice
utilized in the current study
Treatment group Group size (n) Gender
20-month hTau + Veh 12 10 female
2 male
20-month hTau + SB239063 4 4 female
20-month hTau + MW181 8 6 female
2 male
6-month hTau + Veh 3 1 male
2 female
6-month hTau +MW181 4 1 male
3 female
6-month C57BL/6 J (non-Tg) 3 3 male
2-month-old MK2–/– + Veh 3 3 male
2-month-old MK2–/– + LPS 4 4 male
2-month-old C57BL/6 J (non-Tg) + Veh 3 3 male
2-month-old C57BL/6 J (non-Tg) + LPS 4 4 male
LPS lipopolysaccharide, Tg transgenic, Veh vehicle
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Fisher Scientific) and PHF-1 (pS396/pS404; provided by
Peter Davies, Albert Einstein College of Medicine) were
utilized. Phosphorylated p38 MAPK (pT180/pY182),
phosphorylated ATF2 (pT71), and phosphorylated MK2
(pT233) antibodies were from Cell Signaling and total
p38α MAPK antibody was from Thermo Fisher Scien-
tific. The synaptophysin antibody was a kind gift from
Dr Michael Wilson (deceased), and GAPDH antibody
was purchased from Millipore. The following antibodies
were used to mark immune cells: B-cell specific antibody
B220-biotin/CD45R-biotin (R&D Systems), T-cell spe-
cific antibody CD3 (R&D Systems), microglia/macro-
phage specific antibodies Iba1 (Wako), and CX3CR1
(R&D Systems) were utilized.
Tissue preparation and measurement of hippocampal wet
weight
The mice were anaesthetized and transcardially perfused
with 0.125 M phosphate buffer (PB). Following perfu-
sion, the brains were removed, the left hemisphere was
immersion fixed in 4% paraformaldehyde in PB (4%
PFA/PB), the right hemisphere was microdissected into
the cortex and hippocampus, wet weights were recorded,
and the tissues were snap frozen in liquid nitrogen for
subsequent biochemical analysis. The rest of the right
hemispheres were weighed and snap frozen in liquid ni-
trogen for subsequent mRNA extraction.
SDS-PAGE and western immunoblotting
Proteins were homogenized in 10% weight/volume Tis-
sue Protein Extraction Reagent (T-PER®; Thermo Fisher
Scientific) and soluble hippocampal lysates were resolved
via SDS-PAGE and immunoblotted as described previ-
ously [22]. The dilutions of primary antibodies utilized
were as follows: AT180, 1:2500; pATF2, pMK-2, AT8,
PHF-1, and synaptophysin, 1:5000; GAPDH and Tau5,
1:10,000; and phospho-p38α MAPK and total p38α
MAPK, 1:1000.
Sarkosyl-insoluble assay
The Sarkosyl-insoluble fraction of MAPT was isolated
from hippocampal tissues as described before [48], with
minor modifications described previously [22].
Gene expression analysis
RNA from the brain was extracted using the TRIzol® re-
agent as described by the manufacturer (Thermo Fisher
Scientific). Total RNA (100 ng/μl) was converted to cDNA
using the High Capacity cDNA Reverse Transcription kit
and amplified using specific TaqMan probes (gene
expression markers: interferon gamma (IFN-γ, Mm008
01778_m1), IL-1β (IL-1β, Mm00434228_m1), tumor necro-
sis factor alpha (TNFα, Mm00443258_m1), interleukin-6
(IL-6, Mm00446191_m1), interleukin-4 (IL-4, Mm00445
259_m1), Chitinase 3-like 3 (YM1, Mm00657889_m1), Ar-
ginase 1 (ARG1, Mm00475988_m1), and MAPAPK (MK2,
Mm01288465_m1)) and GAPDH was used as a house
keeping gene for normalization. The qPCR assays were run
on the StepOnePlus® Real-Time PCR System (all reagents
were purchased from Thermo Fisher Scientific).
Immunofluorescence, immunohistochemistry, and
quantitative morphometry
Free-floating sections (30 μm thick) were processed for
immunofluorescence or immunohistochemical analysis
as described previously [22]. Briefly, sections were first
incubated in 10 mM sodium citrate buffer (pH 6.0) for
10 min at 95 °C for antigen retrieval, washed in PBS with
0.1% Tween (PBST), and quenched with 0.3% H2O2 in
PBST for 15 min (only for immunohistochemistry). Sec-
tions were blocked for 1 h at room temperature with the
5% normal sera (goat/donkey, from the animal species in
which the secondary antibodies were raised). The sec-
tions were incubated with primary antibodies at the fol-
lowing dilutions: Iba1 and B220-biotin, 1:500; CD3, 1:50;
CX3CR1, 1:100; and AT180, 1:250. After washing in
PBST, the sections were incubated with Alex-Flour® con-
jugated secondary antibodies (1:1000 for immunofluor-
escence; ThermoFisher Scientific) or biotin (1:250 for
immunohistochemistry; Vector Laboratories). Sections
were then either mounted in DAPI Hardset Reagent (for
immunofluorescence) or incubated with Avidin:Biotiny-
lated enzyme Complex (ABC reagent, for immunohisto-
chemistry; Vector Laboratories) reagent for 1 h at RT.
The immunoreactive signals were revealed by developing
sections in SigmaFast® 3,3′-diaminobenzidine (DAB) tab-
lets (Sigma-Aldrich). Bright-field and epifluorescence
images were acquired using a Leica DMR upright fluor-
escence/bright-field microscope.
Tiff images were first converted from 24-bit RGB to 8-
bit gray scale using NIH Image J software for quantita-
tive morphometric analysis (AT180, Iba1, CD3, and
B220). Next, the threshold was set using the image > Ad-
just > Threshold tool for individual images. The thresh-
old in the immunostained areas was set with the Huang
auto-threshold method (display mode black and white)
with minimum and maximum threshold values of 0 and
90 respectively. These values were inversed for the im-
munofluorescence images. After applying the threshold
mask, the total immunoreactive area was calculated
using the Analyze >Measure tool. Prior to running the
measurement tool, the measurements were limited to
the highlighted area threshold by using the tool
Analyze > Set Measurement and selecting the “Limit to
threshold” option. Three different fields (covering the
dorsolateral hippocampal area) per section and three
random sections per mouse brain were scored by an in-
dividual blinded to the treatment/genotype. For the
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quantification of CX3CR1+ cells, three random sections
per mouse brain (n = 3 per condition) were scored
manually for the amount of CX3CR1+ microglia that
appeared activated (with swollen cell body compared
with normal appearing microglia and shorter processes)
in the CA1 region of the hippocampus. Mean ± SEM
values of the CX3CR1+ microglia were plotted. Slides
were coded prior to scoring and the analysis was
performed in a blinded manner.
Y-maze behavioral analysis
A symmetrical Y maze was used to evaluate spatial
working memory [49]. Mice were placed in the center of
the Y maze and allowed to freely explore for one 5-min
trial. The sequence of arm entries was recorded and ana-
lyzed for spontaneous alternation behavior. One spon-
taneous alternation was documented when a mouse
consecutively entered three different arms. Percent
spontaneous alternation was calculated by dividing the
number of alternations by the maximum number of al-
ternation opportunities minus two. The average number
of arms entered over a 5-min period was plotted.
Statistical analysis
Unless otherwise indicated, comparisons between the two
groups were carried out via unpaired t test; comparisons
between multiple treatment groups were performed via
one-way or two-way analysis of variance (ANOVA) with
indicated multiple comparison post-hoc tests. All statis-
tical analyses were performed using GraphPad Prism®.
Results
MW181 and SB239063 treatment rescued inflammation-
induced phosphorylation of tau, p38α MAPK, and ATF2 in
primary neurons
To assess the effects of two brain-permeable p38α MAPK
inhibitors (MW181 and SB239063) on the inflammation-
induced tau hyperphosphorylation, we pretreated primary
cortical neurons either with vehicle (VEH/saline),
SB239063, or MW181 for 30 min and then stimulated the
primary neurons with CM derived from Cx3cr1–/– pri-
mary microglia (Fig. 1a–c). After 90 min of CM treatment,
neurons were lysed and the lysates were processed to de-
tect the level of tau phosphorylation. As reported previ-
ously [22], exchange of 25% of the neuronal supernatant
with Cx3cr1–/– microglia CM led to an increase in tau
phosphorylation on S199/S202 (AT8) and T231 (AT180)
sites (Fig. 1d, e). Notably, the S396/S404 (PHF1) site also
showed a small increase in tau phosphorylation; however,
because of high variability and the fact that mouse tau has
been known to display higher basal levels of phosphoryl-
ation on the PHF1 site, CM treatment did not induce sig-
nificant phosphorylation on the PHF1 site (Fig. 1d, e).
Importantly, preincubation of neurons with MW181 or
SB239063 completely blocked AT8 site and AT180 site
tau phosphorylation (Fig. 1d, e). Interestingly, PHF1 site
phosphorylation of tau was also completely abolished with
MW181 pretreatment (Fig. 1d, e).
To assess the time course of the effects of both
MW181 and SB239063, we first pretreated neurons with
MW181 or SB239063 for 30 min, and then added the
Cx3cr1–/– CM. 20, 40, 60, and 90 min after the addition
of CM, and neurons were harvested for the western blot
analysis. MW181 pretreatment showed its maximum ef-
fect in reducing phosphorylation of p38α MAPK (T180/
Y182) and tau (AT8 site) at 60 and 90 min (Fig. 1f, h).
Whereas the phosphorylation of tau would reflect a
potential direct kinase-substrate event, the phosphoryl-
ation of p38α MAPK by a validated active-site binding,
kinome-selective probe like MW181 [26] would reflect
an indirect effect mediated by feedback mechanisms. In
order to confirm further that the effects of MW181 and
SB239063 were via a p38α MAPK-mediated pathway, we
examined the T71 phosphorylation of ATF2, a well-
established substrate of p38α MAPK [50]. Incubation of
primary neurons with Cx3cr1–/– CM for 90 min in-
creased phosphorylation of pATF2 on T71, which was
significantly blocked by a 30-min pretreatment with
MW181 (Fig. 1j, k). In contrast to MW181, SB239063
showed a biphasic effect with an initial drop in the p-
p38α MAPK and AT8 site tau phosphorylation at
20 min and then again at 60 min after Cx3cr1–/– CM
treatment (Fig. 1g, i). There was a sharp spike in both
p38α MAPK and AT8 site tau phosphorylation at the
40-min time point (Fig. 1g, i). The time-dependent vari-
ability of SB239063 effects on a phosphorylation cascade
in a cell culture system might reflect its multi-kinase inhibi-
tor activity (e.g., [34, 51]), where each kinase target may
have a role that varies quantitatively during the phenotypic
change. This was not pursued further as part of this investi-
gation. Regardless, SB239063 also blocked the increased
phosphorylation of pATF2 on T71 (Fig. 1j, k).
Oral administration of MW181 reduces tau
phosphorylation and aggregation and improves working
memory in 20-month-old hTau mice with an advanced
stage of tau pathology
To test the in-vivo efficacy of MW181 and SB239063,
three separate cohorts of 20-month-old hTau mice were
treated with MW181 (1 mg/kg b.w.; p.o.), SB239063
(5 mg/kg b.w.; p.o.), or vehicle (physiological saline)
once daily for 14 days via oral gavage (Fig. 2a). Twenty-
four hours after the last dose, mice were sacrificed and
the hippocampi were processed for western blot analysis.
A modest reduction in the level of AT180 site tau
phosphorylation was observed in SB239063-treated hTau
mice compared with the vehicle-treated group (Fig. 2b).
Strikingly, once-daily dose of MW181 showed a
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Fig. 2 Oral administration of MW181 reduces hyperphosphorylated and aggregated tau in 20-month-old hTau transgenic mice. a Treatment schema
for intervention for MW181 (1 mg/kg b.w.), SB239063 (5 mg/kg b.w.), or vehicle (saline) administration via oral gavage once daily for a total of 14 days.
After the end date (age 20.5 months), mice were sacrificed for biochemical and neuropathological analysis. b Western blots of detergent soluble hip-
pocampal lysates from 20.5-month-old hTau mice treated with MW181 and SB239063 show significant reduction of AT180 in MW181-treated mice
compared with the vehicle-treated group. c Quantifications of AT180/Tau5 ratio show statistically significant (n = 4 for SB239063, n = 6 for MW181, and
n = 6 for vehicle; mean ± SEM of IDV ratios; **p < 0.01; one-way ANOVA with Tukey’s multiple comparison test) reduction in the AT180/Tau5 ratio in
the MW181-treated compared with vehicle-treated hTau mice. d Outline of the sagittal brain section identifying the hippocampal region used for
quantitative morphometry for AT180. Immunohistochemistry revealed reduced AT180 specifically in the CA3/dentate gyrus of hippocampus of
SB239063-treated and MW181-treated hTau mice compared with vehicle-treated controls. Scale bar: 50 μm (top panels) and 20 μm (bottom panels). e
Quantitative morphometry for AT180 for groups in d (n = 3 mice per genotype; two random fields in three sections per brain were quantified; percent-
age mean ± SEM of AT180 immunoreactive area in the CA3 region of hippocampus; normalized to vehicle-treated group, which was 100%; *p < 0.05;
one-way ANOVA with Tukey multiple comparison test). f, g Reduced levels of Sarkosyl-insoluble and AT8+ tau in the hippocampi of MW181-treated
but not with SB239063-treated 20-month-old hTau mice compared with age-matched, vehicle-treated controls. g Quantifications of Sarkosyl-insoluble/
Sarkosyl-soluble ratios for AT8 (left graphs) and Tau5 (right graphs) show statistically significant (n = 5 for Veh, n = 7 for MW181, and n = 3 for SB239063;
mean ± SEM of IDV; **p < 0.01, ***p < 0.001, **** p <0.0001; unpaired t test) reduction in Tau5 in the Sarkosyl-insoluble fraction of MW181-treated and
SB239063-treated hTau mice. h Twenty-month-old hTau mice treated with vehicle exhibited significantly reduced (*p < 0.05; one-way ANOVA with
Tukey multiple comparison test; n = 5 for vehicle, n = 4 for SB239063, and n = 6 for MW181) percentage of spontaneous alternation compared with
MW181-treated hTau mice in the Y-maze test. No differences in the total number of arms entered were noted. Veh vehicle
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statistically significant reduction in the AT180 site tau
phosphorylation following 14 days of treatment in the
aged hTau mice (Fig. 2b, c).
To confirm the reduction of AT180 site tau phosphoryl-
ation, we performed immunohistochemistry on brains
from 20-month-old vehicle-treated, SB239063-treated, or
MW181-treated hTau mice. We noted a significant differ-
ence in the number of AT180+ neurons in the basolateral
hippocampus, specifically encompassing the CA3 and
dentate gyrus (DG) regions (Fig. 2d), but not in other re-
gions of the hippocampus. Interestingly, quantitative mor-
phometric scoring of the percentage of AT180+ area in
two different fields covering CA3/DG with three sections
per mouse and from three mice per group showed a statis-
tically significant decrease in AT180+ neurons in MW181-
treated but not in SB239063-treated hTau mice (Fig. 2e).
Next, we performed the Sarkosyl-insoluble assay in the
hippocampus to determine whether the reduction in
AT180 site tau hyperphosphorylation in the MW181-
treated and SB239063-treated group led to any alterations
in tau aggregation. Notably, all four vehicle-treated 20-
month-old hTau mice showed a very clear presence of
Tau5+ bands (total tau) in the Sarkosyl-insoluble fraction
compared with MW181-treated and SB239063-treated
hTau mice (Fig. 2f), suggesting this treatment reduced tau
aggregation/NFT pathology. Sarkosyl-insoluble tau in the
vehicle-treated group was phosphorylated at the AT8 site
(Fig. 2f). Analysis of the Sarkosyl-insoluble/Sarkosyl-sol-
uble ratio for Tau5 showed a statistically significant reduc-
tion in the levels of Sarkosyl-insoluble aggregated tau in
MW181-treated and SB239063-treated hTau mice com-
pared with the vehicle-treated group (Fig 2g). Because of
the variability, the difference in the Sarkosyl insoluble/sol-
uble ratios for AT8 showed statistically significant reduc-
tion only with MW181, but not with SB239063 treatment,
compared with vehicle (Fig. 2g).
Previous studies have suggested that hTau mice exhibit
various behavioral and cognitive impairments by 20 months
of age [52]. To determine whether MW181-mediated re-
duction in tau pathology translates to improved behavioral
function, 20-month-old hTau mice treated with vehicle,
SB239063, or MW181 were subjected to Y-maze behavioral
analysis. While the total number of arm entry was indistin-
guishable between vehicle-treated, SB239063-treated, and
MW181-treated groups (Fig. 2h), hippocampal-dependent
working memory was significantly improved in SB239063-
treated and MW181-treated hTau mice compared with
vehicle-treated controls because the SB239063-treated or
MW181-treated hTau mice displayed a significantly ele-
vated spontaneous alternation score in the Y-maze test
(Fig. 2h). Together, these results suggest that SB239063 and
MW181 could reduce tau hyperphosphorylation and aggre-
gation as well as improve working memory in 20-month-
old hTau mice.
In-vivo administration of MW181 reduces the level of
pMK2 and pATF2, and increases synaptophysin in
20-month-old hTau mice
To better link the reduced tau hyperphosphorylation
and aggregation in the MW181-treated aged hTau mice
to a decrease in p38α MAPK activity, we assessed the
phosphorylation of downstream pathway targets: pATF2
(T71) and pMK2 (pT334). Unlike cell culture studies,
the levels of p-p38/T-p38α MAPK in MW181-treated or
SB239063-treated mice did not significantly decrease
compared with vehicle-treated groups (Fig. 3a, b).
MW181-treated aged hTau mice showed a significant re-
duction in both pATF2 and pMK2 compared with
vehicle-treated groups (Fig. 3a, c, d). These results indi-
cate that MW181 can significantly affect the in-vivo
catalytic activity of p38α MAPK with a resultant reduc-
tion in the site-specific phosphorylation of known sub-
strates (T71 and T334 sites in ATF2 and MK2,
respectively). This was not observed with SB239063.
A previous study demonstrated elevated synaptophysin
levels following p38α MAPK inhibition using a mixed
kinase inhibitor on IL-1β stressed neurons in culture
[24]. To determine whether in-vivo treatment with
MW181 alters synaptophysin levels, we performed west-
ern blot analysis for synaptophysin in the hippocampus
of MW181-treated 20-month-old hTau mice. There was
a statistically significant increase in synaptophysin in
MW181-treated 20-month-old hTau mice compared
with vehicle-treated mice (Fig. 3a, e). SB239063 induced
a modest increase in synaptophysin levels; however, the
difference (versus vehicle control) was not statistically
significant when analyzed with multiple comparisons via
one-way ANOVA (Fig. 3a, e). It is important to note that
effect of SB239063 on pMK2 and synaptophysin levels
was arithmetically superimposable with those of
MW181, although statistical significance was not
reached because of the limited number of animals used
in SB239063-treated groups compared with those in
MW181-treated groups.
MW181 blocks IFNγ and IL-1β expression and promotes
alternative immune activation
Activation of both ATF2 and MK2 may lead to the expres-
sion of various proinflammatory cytokines/chemokines in-
cluding IL-1β. Inhibition of p38α MAPK by MW181, but
not by SB239063, led to a significant decrease in both
IFNγ and IL-1β expression in the 20-month-old hTau
mice (Fig. 3f). Interestingly, both IL-6 and TNFα levels
also displayed marginal reduction with MW181 treatment
during this same time. However, the differences were not
statistically significant (Fig. 3f). Furthermore, an increase
in the level of YM1 and ARG1, which are markers of alter-
native activation, showed an increased trend in MW181-
treated hTau mice, but did not reach statistical significance
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Fig. 3 MW181 reduced the levels of pATF2 and pMK2, increased levels of synaptophysin, and blunted the expression of IFNγ and IL-1β in 20-month-
old hTau mice. a Western blot analysis of hippocampal lysates shows no significant difference in p-p38α MAPK (pT180/pY182) levels, but reduced levels
of phosphorylated ATF2 (pT71) and phosphorylated MK2 (pT334) and increased levels of synaptophysin were observed with MW181 treatment. b–e
Quantification shows no difference for p-p38α MAPK, but statistically significant reduction (n = 3 for SB239063, n = 8 for MW181, and n = 5 for vehicle;
mean ± SEM of IDV ratios; *p < 0.05; **p < 0.01; one-way ANOVA with Tukey’s multiple comparison test) in the pATF2/GAPDH and pMK2/GAPDH ratios
in MW181-treated hTau mice compared with vehicle-treated hTau mice. None of these proteins were seen to be statistically altered with SB239063
treatment. f Quantitative real-time PCR analysis for various markers of classical activation or M1 state (IFNγ, IL-1β, TNFα, and IL-6) and alternative
activation or M2 state (IL-4, YM1, and ARG1) shows a significant reduction (n = 3 for SB239063 and n = 6 for MW181 and vehicle; mean ± SEM of IDV ra-
tios; *p < 0.05; two-way ANOVA with Tukey’s multiple comparison test) in the levels of IFNγ and IL-1β in the MW181-treated hTau mice compared with
vehicle-treated hTau mice. g Immunohistochemical and immunofluorescence analysis shows Iba1+ microglia and CD45+ microglia/macrophages in
the CA3 region of hippocampus, B220+ B cells and CD3+ T cells in the meninges, and CX3CR1+ microglia in the CA3 region of the hippocampus in
MW181-treated, Veh-treated, or SB239063-treated 20-month-old hTau mice. Scale bars: 30 μm for Iba1, CD45, and B220; 10 μm for B220 and CD3. h
Quantitative morphometry for Iba1, B220, CD3, and CX3CR1 for immunochemistry in g (n = 3–4 mice per genotype); four random fields in three
sections per brain were quantified; mean area (± SEM) immunoreactive for Iba1, B220, and CD3 in the hippocampus (for Iba1) or in the meninges (for
CD3 and B220). For CX3CR1, the number of CX3CR1+ microglia displaying activated morphology (reduced processes and swollen cell body) was
counted manually in the CA1 region of hippocampus and expressed as number of cells per mm2 (*p < 0.05; one-way ANOVA followed by Tukey
multiple comparison post-hoc test). Note that B220 and CD3 showed a reduced trend in MW181-treated groups but were not statistically significant,
unlike Iba1 and CX3CR1 which were significant. Veh vehicle
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(Fig. 3f). To determine whether the pattern of gene ex-
pression observed for the inflammatory cytokines/chemo-
kines would reflect the morphological alterations of
microglia and peripherally derived macrophages, we per-
formed a series of immunohistochemical and immuno-
fluorescence experiments. Notably, Iba1+/CX3CR1+
microglia appeared more resting in the CA3 region of
hippocampus of MW181-treated and SB239063-treated
20-month-old hTau mice compared with vehicle-treated
hTau mice (Fig. 3g). Qualitatively, no differences were ob-
served for CD45+ microglia/peripherally derived macro-
phages across different treatment groups (Fig. 3g), and
therefore no further quantitative morphometric analysis
was performed. Since IFNγ is primarily secreted by T cells
and was more than four-fold higher in SB239063-treated
hTau mice compared with vehicle-treated controls and
that MW181 treatment significantly reduced IFNγ expres-
sion levels, we also assessed the presence of T cells and B
cells in brain sections of hTau mice treated with vehicle,
MW181, or SB239063. Immunofluorescence analysis re-
vealed the presence of qualitatively more B220+ B cells
and CD3+ T cells in the meninges of vehicle-treated and
SB239063-treated 20-month-old hTau mice compared
with those treated with MW181 (Fig. 3g). We did not ob-
serve presence of any parenchymal B cells/T cells in any
treatment groups. Upon quantification, we observed
statistically significant reduction in the Iba1 immunoreac-
tivity and the number of CX3CR1+ activated microglial
cells, but not in the CD3+ T cells/B220+ B cells, in
MW181-treated or SB239063-treated groups compared
with vehicle-treated 20-month-old hTau mice (Fig. 3h).
Together, these results suggest that primarily MW181, but
to a lesser extent SB239063, are both capable of suppress-
ing proinflammatory responses, while inducing alternative,
more neuroprotective, anti-inflammatory responses in the
brain.
MK2–/– mice are resistant to LPS-induced tau phosphorylation
and show reduced levels of total p38αMAPK
We have demonstrated previously that intraperitoneal
administration of LPS results in elevated tau phosphoryl-
ation within the brain and that mice deficient for toll-
like receptor 4 (TLR4) or IL-1β receptor (IL-1R) are re-
sistant to this LPS-induced tau phosphorylation [22].
Since p38α MAPK inhibition by MW181 leads to both
MK2 deactivation and reduced tau phosphorylation
(Fig. 3), we tested whether MK2 deficiency would
prevent LPS-induced tau phosphorylation in vivo. Two-
month-old nontransgenic and MK2–/– mice were
administered a single dose of LPS (10 mg/kg b.w.; i.p.).
After 24 h, the hippocampi were processed for biochem-
ical analysis. First, we assessed whether MK2–/– mice are
deficient for MK2 via quantitative real-time PCR ana-
lysis. Compared with 2-month-old nontransgenic mice,
MK2–/– mice displayed a statistically significant reduc-
tion in MK2 gene expression (Fig. 4a), suggesting the de-
ficiency of MK2 in MK2–/– mice. Next, we performed
western blot analysis of the hippocampus to assess tau
phosphorylation and p38 MAPK activation (phosphoryl-
ation). As reported previously [22], a single injection of
LPS led to AT8 and AT180 site tau phosphorylation in
nontransgenic mice (Fig. 4b–d). Unlike nontransgenic
mice, MK2–/– mice did not show an elevation in AT8 or
AT180 site tau phosphorylation (Fig. 4b–d). There was
also no significant effect of either LPS or MK2 deficiency
on PHF1 site tau phosphorylation (Fig. 4b, e). Although
there was no difference in the p-p38α MAPK (T180/
Y182) levels observed in either nontransgenic or MK2–/–
groups, interestingly, total p38α MAPK levels were sig-
nificantly reduced in vehicle-treated MK2–/– mice
compared with vehicle-treated nontransgenic mice
(Fig. 4b, f ). These results suggest that MK2–/– mice are
resistant to LPS-induced tau phosphorylation and that
the deficiency of MK2 is correlated with reduced total-
p38α MAPK levels.
Discussion
There are three major findings in this study; MW181
can reduce inflammation-induced p38α MAPK activa-
tion and tau phosphorylation in primary neurons in
vitro; MW181 can block tau phosphorylation and aggre-
gation in a 20-month-old hTau mouse model of tauopa-
thy with an advanced stage of tau pathology; and
evidence consistent with a p38 MAPK-mediated pathway
playing an important role in tau pathology was provided
by the resistance of MK2–/– mice to inflammation-
induced tau hyperphosphorylation. These results identify
p38α MAPK as a druggable target that can block
inflammation-induced tau pathology and improve cogni-
tive function in tauopathies.
Mitogen-activated protein kinase (p38α MAPK is one of
the members of this large family of kinases) is associated
with various cellular processes including cell division [53],
immunity [54], differentiation, oncogenesis [55], neurogen-
esis, and apoptosis [56] as well as learning and memory
[57] (reviewed in [58, 59]). In AD/tauopathies, MAPKs play
various roles at different stages of disease [60]. p38α MAPK
can play an important role both in amyloid-mediated and
tau-mediated toxicities. First, p38α MAPK has been shown
to mediate Aβ-induced expression of various proinflamma-
tory cytokines/chemokines from microglial cells that causes
neuroinflammation [25, 26, 29, 35]. Targeted inactivation of
p38α MAPK with small molecule inhibitors prevents the
production of proinflammatory cytokines, reduces neurode-
generation, and improves neuronal and cognitive functions
in rodent models of amyloid pathology [25, 26, 29, 35].
Second, in neurons, p38α MAPK has been shown to act
as an important kinase in inducing IL-1β-mediated
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hyperphosphorylation of tau [24, 61]. Our previous study
suggested that enhancement of microglia-specific neuro-
inflammation via genetic deficiency of Cx3cr1 resulted in
accelerated tau pathology and cognitive impairment in an
hTau mouse model of tauopathy [22]. Furthermore, hyper-
phosphorylation of tau in this model was mediated by
upregulation of p38α the MAPK pathway, but not GSK3β
or CDK5 pathways [22]. In a recent study, we demon-
strated that adoptive transfer of reactive microglia from
hTau-Cx3cr1–/– mice led to induction of tau hyperpho-
sphorylation and aggregation within the brains of recipient
mice, which was also mediated via the IL-1β–p38α MAPK
signaling pathway [23].
To our knowledge, this report provides the most conclu-
sive demonstration that selective inhibition of p38α MAPK
alone can significantly reduce Sarkosyl-insoluble NFTs,
increase synaptophysin, and reduce the expression of pro-
inflammatory cytokines in a pure tauopathy model with
advanced stages of disease. Notably, original reports on
hTau mice suggested formation of mature tangles and neu-
rodegeneration by 20 months of age [45, 62, 63]. However,
a recent study by our group has suggested that deficiency
of microglial Cx3cr1 can enhance neuroinflammation and
lead to the formation of Sarkosyl-insoluble tau in hTau
mice as early as 2 months of age [23]. The potency of
MW181 to reduce NFTs and rescue cognitive function
suggests the therapeutic potential of selectively targeting
p38α MAPK to attenuate tau pathology and cognitive
impairment. While 1 mg/kg b.w. of MW181 was the only
tested dose in the present study, different dosing and dura-
tions of treatment are key considerations during medical
chemistry optimization of an in-vivo molecule for pharma-
cological safety. Just as our tauopathy studies described
here were being completed, a recent drug development re-
port [25] described a MW181 analog optimized for such
key drug development compliances. While the anti-NFT
effects of MW181 (via p38α MAPK inhibition) on 20-
month-old hTau mice observed here are very intriguing,
our study has some limitations. First, as far as we know,
this is the first study targeting p38α MAPK in a 20-month-
old mouse model of tauopathy, which is equivalent to
approximately 60 years of age in humans, and demonstrat-
ing beneficial effects. Therefore, it should be validated in a
separate study by a different group. Second, we did not
perform parallel comparisons with nontransgenic mice
administered with MW181, which might be important to
determine whether MW181 effects are specific for trans-
genic mice or whether they have an overall affect in a nor-
mal system. Finally, in view of the normal physiological
functions of p38 MAPK within the CNS, it is important to
note that MW181 did not completely abolish the levels of
activated forms of p38α MAPK. This further supports the
possibility of modulatory effects of MW181 in selectively
ablating the excessively activated forms of p38α MAPK.
Another important consideration related to the select-
ivity of MW181 for the α isoform of p38 MAPK is that
Fig. 4 MK2-deficient mice are resistant to LPS-induced tau phosphorylation and show reduced p38α MAPK. a Quantitative real-time PCR analysis
for MK2 in the brains of 2-month-old nontransgenic vs. MK2–/– mice confirms a significant knockdown of MK2 in these mice (n = 4 for non-Tg
and n = 3 for MK2–/– mice; ***p < 0.0001; unpaired t test; mean ± SEM). b Western blots of detergent soluble hippocampal lysates from 2-month-
old nontransgenic and MK2–/– mice treated with either vehicle (VEH) or LPS (10 mg/kg b.w.; intraperitoneal; single dose for 24 h). Note the LPS-
induced AT8 and AT180 site tau phosphorylation in LPS-treated nontransgenic mice, which is reduced in MK2–/– mice. No significant difference is
seen in PHF1-antibody specific tau phosphorylation and phosphorylated p38α MAPK (pT180/pY182) levels. However, the total p38α MAPK levels
are reduced in MK2–/– mice. c–e Quantifications of the western blots in b show a statistically (n = 3 mice per group; mean ± SEM of IDV ratios of
AT8/Tau5 and AT180/Tau5; **p < 0.01; two-way ANOVA with Bonferroni’s multiple comparison test) significant increase in IDV ratios for AT8/Tau5
and AT180/Tau5 in LPS-treated non-Tg, but not in LPS-treated MK2–/– mice. f Quantifications of the total-p38α MAPK levels show statistically sig-
nificant reduction in the levels of total-p38α MAPK/GAPDH IDV ratio (n = 3 per group; mean ± SEM; **p < 0.01; unpaired t test) in MK2–/– mice
compared with nontransgenic mice. Tg transgenic
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MW181 is a representative member of efficacious and
CNS-penetrant small molecule p38α inhibitors that
large-scale kinome screens show are selective for the
p38 MAPK family, lack crossover to major G-protein-
coupled receptor (GPCR) agonist or antagonist classes
based on functional screens, exhibit low toxicity at high
doses, and are efficacious in an AD amyloid-relevant
and progressive brain injury models [25, 26]. The select-
ivity of MW181 action is further indicated by the failure
to bring about its CNS-relevant pharmacodynamic
effects in p38α MAPK inhibitor-resistant mice [26, 28].
Further, the high-resolution crystal structure of MW181
and other members of this class of highly selective,
in-vivo efficacious p38 MAPK inhibitor probes reveals
that the structural basis of this selectivity is their
common chemical scaffold that exploits specific
three-dimensional features found only in p38 MAPK
[25, 26]. Taken in its entirety, an extensive body of
evidence indicates that the pharmacodynamic effects
of this class of novel, selective inhibitors of CNS
p38α MAPK are via modulation of endogenous p38α
MAPK. In our previous study, the X-ray diffraction
data revealed that the MW181 presence in the active
site of the p38α MAPK renders the kinase to become
inactive [25, 26]. This is an important consideration
because the MW181-mediated inhibition may be en-
tirely independent of the phosphorylation status of
p38α MAPK on T180/Y182 sites. In other words,
even if the p38α MAPK show unchanged T180/Y182
phosphorylation, binding of MW181 at the active sites
makes the kinase inactive. Therefore, it is important
to assess the activation status of p38α MAPK via
assessing the phosphorylation of its downstream tar-
gets such as ATF2 and MK2. Indeed, this is the rea-
son why we observed no alterations in the levels of
pT180/pY182 in p38α MAPK in vivo but we did in
vitro (Figs. 1 and 3). To some extent, the levels of
pT180/pY182 in p38α MAPK could also be attributed
to the extent of autophosphorylation by itself [64].
Therefore, we confirmed MW181-mediated p38α
MAPK inhibition by assessing pATF2 both in vitro
and in vivo. Optimized p38 MAPK inhibitors in this
novel class of small molecules, such as MW150 [25],
will also address the issue of drug candidate specifi-
city and safety. Regardless, the results shown here
added increasing support to the hypothesis that p38α
MAPK is the key tau kinase under inflammatory con-
ditions. While our previous studies suggested that
MW181 may possibly target the β isoform of p38
MAPK and Nemo-like kinase (NLK) MAPK at rela-
tively higher Ki values (322 nM and 199 nM, respect-
ively) compared with p38α MAPK (184 nM) [26], it is
the α-isoform selective inhibition of p38 MAPK that
reduces tau phosphorylation and cytokine production.
This conclusion is based on earlier studies, which
suggested that deletion of the β isoform of p38
MAPK did not affect LPS-induced cytokine produc-
tion or induce inflammation, suggesting that p38α
MAPK is the primary mediator of cytokine release
and inflammation [65] and that NLK is not an in-
ducer, but a suppressor, of NF-κB activity [66], which
is the primary mediator of inflammation. Taken to-
gether, these results suggest that the effects observed
for MW181 in the current studies are exclusively due
to targeted inhibition of the α isoform of p38 MAPK.
In the current study, MK2-deficient mice demonstrate
a strong resistance to LPS-induced tau hyperphosphory-
lation. This suggests that suppression of IL-1β and re-
lated proinflammatory cytokine secretion is inhibited in
MK2–/– mice, which are otherwise induced by MK2-
mediated transcription [67]. If this scenario was to be
true, then one would argue that p38α MAPK should still
be able to phosphorylate tau in the absence of MK2. Be-
cause IL-1β is one of the key proinflammatory cytokines
important for LPS-induced p38α MAPK activation and
the deficiency of MK2 leads to ablation of IL-1β produc-
tion, then this suggests there is lack of a sufficient trig-
ger for the activation of p38α MAPK following LPS
injections (due to reduced expression of IL-1β and other
proinflammatory cytokines). Indeed, our results show a
significant reduction in the total p38 MAPK levels in
MK2-deficient mice, suggesting insufficient levels of
p38α MAPK in MK2–/– mice. An alternative argument
would be that MK2 itself might serve as a potential tau
kinase. While this possibility needs further careful
characterization, it is important to note that the MK2
activation via phosphorylation (at T222, S272, and T334)
by p38 MAPK happens within the nucleus. Because of
this, there is a very unlikely chance for the activated
(and possibly p38 MAPK bound) MK2 to physically
interact with tau, unless it translocates to the cytoplasm
after activation. Therefore, based on current evidence, it
is conceivable that reduced LPS-induced tau phosphor-
ylation in MK2 deficient mice is due to the feed-forward
abrogation of the MK2 > IL-1β > IL-1R > p38α MAPK >
tau axis.
Conclusions
The results reported in this article provide a clear
validation of p38α MAPK as a target whose selective
inhibition can result in improved outcomes in tauopa-
thy models. The recent description [25] of a drug
candidate that retains all of the positive attributes of
MW181, but is further optimized for bioavailability
and in-vivo safety, provides the means to extend the
rationale presented here for tauopathies toward clin-
ical proof of concept.
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